Trickle holding PCOP bundles its software divisions into one subsidiary:
>>Pharmacopeia Announces Accelrys, a New Leader in Scientific Software
- Accelrys to Represent the Best in Software For Chemical and Pharmaceutical Research -
PRINCETON, N.J., Apr 2, 2001 /PRNewswire via COMTEX/ -- Pharmacopeia, Inc. (Nasdaq: PCOP chart, msgs) today introduced Accelrys, a new identity for its software subsidiary. Accelrys is formed from the combination of four leading specialist companies owned by Pharmacopeia -- Molecular Simulations Inc. (MSI), Synopsys Scientific Systems, Oxford Molecular, and the Genetics Computer Group (GCG). The 2000 pro forma revenues of this business exceeded $90 million. Pharmacopeia's software subsidiaries will begin operating as Accelrys on June 1, 2001.
Pharmacopeia operates two related businesses. Pharmacopeia's Drug Discovery business is a leader in experimentation-based technologies and services for the pharmaceutical and biotechnology industries. Accelrys is the first company to offer a complete spectrum of integrated scientific software and related consulting services to accelerate pharmaceutical discovery and chemical development. Pharmacopeia's Chairman, President, and Chief Executive Officer, Dr. Joseph A. Mollica, said the debut of Accelrys signals a new era for Pharmacopeia, "Our two businesses will continue to work closely together to ensure that our software products are optimized to real laboratory environments, and that our Drug Discovery business is equipped with the state-of-the-art in simulation and informatics."
Dr. Michael Stapleton, Chief Operating Officer, unveiled the name, structure, and objectives of Accelrys at the American Chemical Society (ACS) meeting in San Diego. Accelrys is the product of an integration process that has combined the organizations, products, technologies, and creative visions of its four component companies.
According to Dr. Stapleton, the result is a new leader in scientific software, "Accelrys will provide the pharmaceutical and chemical industries with the best science and technology in simulation, bioinformatics, cheminformatics, workflow, and decision support. We gain significant value from the interaction and integration of these technologies. The scale of our new operation allows us to invest more effectively in our R&D and to develop services to be offered by our new Consulting Group." Accelrys has over 500 employees located worldwide. Sites include major Centers of Excellence in San Diego CA, Princeton NJ, and Cambridge UK, and Technology Centers in Leeds UK and Madison WI.
Dr. Stapleton explained the company's strategy, "We will continue to extend our capabilities across a product range encompassing genomics, structural biology, and the design and development of drugs, materials, and chemical processes. Across these activities, we will facilitate the creation, management, and use of chemical and biological information. We will integrate our technologies with each other, with personal productivity tools, and with corporate IT infrastructures. Our vision is of an integrated software platform supporting enterprise-wide R&D decisions."
Accelrys also introduced its new Consulting Services group at the ACS Meeting. "This new, highly skilled team is the best way to meet the unique needs of our clients," said Robert J. White, Senior Vice President of Sales and Consulting Services at Accelrys. "Consulting Services is a great team of expert scientists and software engineers who understand customers' businesses and research processes, and work with them to develop solutions tailored to their requirements and corporate systems."
Pharmacopeia (http://www.pharmacopeia.com) is a leader in enabling science and technology that improves and accelerates drug discovery and chemical development. Pharmacopeia's Software segment develops and commercializes gene sequence analyses, molecular modeling and simulation, cheminformatics, bioinformatics, workflow, and decision support software for the life sciences and materials research. It also provides consulting services to its customers in drug discovery and chemical development. Pharmacopeia's Drug Discovery segment integrates proprietary small molecule combinatorial and medicinal chemistry, high-throughput screening, in-vitro pharmacology, computational methods, and informatics to discover and optimize lead compounds and to accelerate customers' drug discovery efforts. Pharmacopeia employs approximately 750 people, generated 2000 revenues of approximately $119 million, and is headquartered in Princeton, NJ<<
snip
Cheers, Tuck |
